Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
13.5.2021 10:30:00 EEST | Business Wire | Press release
Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan, Representative Director, President and CEO: Hiroshi Nomura) has announced that they will initiate a Phase 1 clinical study of DSP-0038 in the United States for the treatment of Alzheimer’s disease psychosis.
DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma to treat obsessive-compulsive disorder, and Exscientia’s immuno-oncology agent, EXS-21546, announced earlier this year.
Joint research between Exscientia and Sumitomo Dainippon Pharma designed DSP-0038 to be a single small molecule that exhibits high potency as an antagonist for the 5-HT2A receptor and agonist for the 5-HT1A receptor, whilst selectively avoiding similar receptors and unwanted targets, such as the dopamine D2 receptor. Selective dual targeting is a major challenge for conventional drug discovery, and psychiatric indications also require exceptional selectivity to avoid off-target effects. The successful design of DSP-0038 demonstrates opportunities to design selective molecules with dual activity.
DSP-0038 will be assessed for improved antipsychotic effects associated with Alzheimer’s disease psychosis, as well as improvements in behavioural and psychological symptoms of dementia which include agitation, aggression, anxiety, and depression.
Toru Kimura, Representative Director, Executive Vice President and Chief Scientific Officer of Sumitomo Dainippon Pharma, said: "We have been impressed by the outstanding productivity of Exscientia's AI technologies. The combination of Exscientia’s AI with our company’s deep experience in monoamine GPCR drug discovery has now led to two molecules reaching our clinical pipeline from this collaboration.”
Andrew Hopkins, CEO of Exscientia, said: "This is further validation that our AI platform can turn complex biological challenges into high-quality clinical candidates quickly. To have what we believe to be the world’s first three clinical molecules created using AI arising from our own platform – two with Sumitomo Dainippon Pharma - is a wonderful achievement. We hope that through the creation of DSP-0038 improved treatments for Alzheimer’s disease psychosis will be realized."
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed two drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma defines its corporate mission as "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." By pouring all our efforts into the research and development of new drugs, we aim to realize our corporate mission and provide innovative and effective pharmaceutical
solutions to people not only in Japan but also around the world. Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas of Psychiatry & Neurology, Oncology and Regenerative Medicine/Cell Therapy. For further details, visit https://www.ds-pharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005059/en/
Contact information
Enquiries:
Edelman
Anitra Sprauten
P: +44 (0)7896 859386
Anitra.Sprauten@edelman.com
Stephanie Crisp
P: +44 (0)7583 003417
Stephanie.Crisp@edelman.com
For Exscientia
Mark Swindells: contact@exscientia.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Western Europe’s Fashion E-commerce Market Matures, Representing 20% of Online Consumer Spending as Gen Z Drives momentum30.7.2026 10:00:00 EEST | Press release
Fashion remains one of the largest and most resilient categories in Western European e-commerce, accounting for approximately 20% of online consumer spending across key markets, according to the latest NIQ (NYSE: NIQ) report, Decoding the Fashion E-commerce European Market in 2026. The study analyzes the behaviour of more than 2 million online shoppers across 10 European countries, providing one of the most comprehensive views of the region’s online fashion landscape. While fashion continues to play a central role in e-commerce, the category is entering a new phase of maturity. Across Europe, total e-commerce sales grew by 5% over the past year, compared with 3% growth for online fashion sales, highlighting the need for brands and retailers to find new avenues for growth. Key findings of the report: Fashion remains a core e-commerce category Fashion represents around one-fifth of total online spending across Western Europe. It remains one of the largest e-commerce sectors, second only
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track30.7.2026 09:37:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter and under a new operating model, Takeda remains on track to deliver its strategic and financial commitments for the fiscal year. FY2026 First Quarter Highlights Revenue increased by +10.2% versus the prior-year period on an actual exchange rate (AER) basis and decreased by -0.5% on a Constant Exchange Rate (CER) basis as the negative impact of the loss of exclusivity of VYVANSE® was largely offset by growth from core in-line brands. Core Operating Profit increased by +11.5% on an AER basis and decreased by -0.5% on a CER basis, r
Coulson Aviation Introduces CFR HALO, a Long-Term Fire Retardant Engineered for Modern Aerial Firefighting30.7.2026 09:03:00 EEST | Press release
Coulson Aviation today introduced CFR HALO, a next-generation long-term fire retardant engineered specifically for modern aircraft, tank systems, and wildfire missions. It is the first product from Coulson EmberWorks, the company’s research and development division dedicated to advancing aerial firefighting technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729960073/en/ Coulson Aviation has introduced CFR HALO, a next-generation long-term fire retardant engineered specifically for modern aircraft, tank systems and wildfire missions. It is designed with mission-optimized viscosity and flow characteristics to improve drop cohesion, reduce airborne drift, and support more accurate placement within the intended target area. CFR HALO is currently advancing through independent qualification programs with CEREN in France and the USDA Forest Service for inclusion on the Qualified Products List (QPL). These programs wil
SES Reports H1 2026 Results & Reiterates Full-Year Outlook30.7.2026 08:30:00 EEST | Press release
SES S.A. announces financial results for the three and six months ended June 30, 2026. H1 2026 Performance (€ million) H1 2026 as reported (1) H1 2025 as reported (1) ∆ At constant FX (2) H1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.17 1.08 1.08 Revenue 1,602 978 +72.4% 1,799 -5.0% Adjusted EBITDA (4) 725 521 +47.0% 824 -6.2% 1) ‘Reported basis’ with Intelsat fully consolidated from July 17, 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralize currency variations 3) ‘Like-for-like basis’ is as if Intelsat was fully consolidated from January 1, 2024 4) Excluding operating expenses/income recognized in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +89.0% yoy(1) supported by growth in Mobility (+169.9% yoy(1); including positive impact from a contract restructuring in
AB InBev Reports Second Quarter 2026 Results30.7.2026 08:02:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729033132/en/ Regulated information1 “Cheers to beer – our performance this quarter reflects the strength of the beer category and the consistent execution of our strategy. Through investment in our megabrands and mega platforms, innovation and offering more choices across more occasions, we are strengthening the cultural relevance of our brands with consumers. Thank you to our colleagues for their commitment and disciplined execution, which position us well to continue our momentum.” – Michel Doukeris, CEO, AB InBev Revenue +5.6% Revenue increased by 5.6% in 2Q26 with revenue per hl growth of 4.2% and by 5.7% in HY26 with revenue per hl growth of 4.3%. Reported revenue increased by 11.0% in 2Q26 to 16 660 million USD and by 11.5% in HY26 to 31 927 million USD, positively impacted by currency translation. 6.2%
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom